Cardiology

Back to articles

PCSK9 inhibitors not seen as cost-effective options

KEY POINT

Results of a cost-effectiveness analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) found that these agents are not cost effective, and their use would contribute to a substantial increase in U.S. health care costs.